NCT03772041View on ClinicalTrials.gov

Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure

PHASE3CompletedINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

January 16, 2019

Primary Completion Date

July 21, 2020

Study Completion Date

July 29, 2020

Conditions
Congestive Heart Failure
Interventions
DRUG

OPC-61815

Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg

DRUG

Tolvaptan Tab 15 MG

Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo

Trial Locations (1)

Unknown

Saiseikai Kumamoto Hospital, Kumamoto

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY